摘要
肺癌是发病率最高的恶性肿瘤,KRAS是非小细胞肺癌(non-small cell lung cancer,NSCLC)的主要突变基因之一。关于KRAS的治疗存在疗效不佳、特异性不强、安全性不足等问题,使得KRAS突变型非小细胞肺癌成为目前的研究热点。文章就KRAS突变型非小细胞肺癌的靶向和免疫治疗的机制、疗效等作一综述,以期为下一步相关研究提供方向和目标。
Lung cancer is the malignancy with the highest incidence,and KRAS is one of the main mutated genes in non-small cell lung cancer.The treatment of KRAS has problems such as poor efficacy,weak specificity and insufficient safety,which makes KRAS mutant non-small cell lung cancer a research hotspot.This article reviews the mechanism and efficacy of targeted therapy in KRAS mutant non-small cell lung cancer,in order to provide directions and goals for the future research.
作者
侯雪楠
郭泽怀
曹洋
HOU Xuenan;GUO Zehuai;CAO Yang(The First Clinical School of Guangzhou University of Chinese Medicine,Guangdong Guangzhou 510405,China;Department of Medical Oncology,the First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangdong Guangzhou 510405,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第17期3325-3330,共6页
Journal of Modern Oncology
基金
国家自然科学基金面上项目(编号:82174456)
广州中医药大学第一附属医院创新强院二期工程(编号:2019IIT27)。
